Compass Pathways Accelerates Psilocybin Therapy Approval Timeline
Event summary
- Compass Pathways reported Q1 2026 net income of $91.2M, up from a $17.9M loss in Q1 2025, driven by a $130.9M non-cash gain on warrant valuation.
- The company's rolling NDA submission for COMP360 psilocybin therapy is underway, with final submission expected in Q4 2026.
- Compass received a Commissioner’s National Priority Review Voucher (CNPV) which could accelerate FDA review by 1-2 months.
- Cash position grew to $466M as of March 31, 2026, up from $149.6M at year-end 2025.
The big picture
Compass Pathways is positioning itself at the forefront of the psychedelic therapy revolution, with COMP360 potentially becoming the first FDA-approved psilocybin treatment for treatment-resistant depression. The company's accelerated regulatory path and strong cash position suggest it's well-positioned to capitalize on growing demand for innovative mental health solutions. The White House's involvement highlights the strategic importance of this emerging therapeutic category.
What we're watching
- Regulatory Momentum
- Whether the CNPV and White House executive order will actually reduce COMP360's review timeline by 1-2 months.
- Commercial Readiness
- The pace at which Compass can scale its delivery infrastructure across 7,300+ treatment centers.
- Market Dynamics
- How COMP360's differentiated clinical profile will position it against potential competitors in the psychedelic therapy space.
Related topics